Hemab Therapeutics has raised $157 million in Series C funding, led by Sofinnova Partners with participation from Avoro Capital Advisors, RA Capital Management and Novo Holdings, among others. The capital will support the advancement of the company’s pipeline of prophylactic therapies for serious bleeding and thrombotic disorders.
As announced by the company this morning, Hemab’s lead program, sutacimig, is being developed as the first preventive treatment for Glanzmann thrombasthenia. The new financing follows completion of its Phase 2 study and will fund a registration study planned for 2026.
The company is also advancing HMB-002 toward a registration study. The antibody-based therapy for Von Willebrand disease has shown in Phase 1 studies to increase both Von Willebrand Factor and Factor VIII, directly targeting the disorder’s root cause.
Additionally, Hemab plans to introduce a third program, HMB-003, in the first half of 2026.
In conjunction with the funding news, Sofinnova Partners’ Joe Anderson will join Hemab’s board of directors.
